Docket #: S23-099
Massively Parallel Mixed Lymphocyte Reactions
Stanford researchers have developed technology enabling pooling and simultaneous testing of engineered T cells from multiple human donors. This invention increases scale and reduces costs for diagnostic, and pre-clinical development of engineered T cell therapies.
Engineered immune cell testing, particularly CAR-T cells, is costly and time-consuming. A major challenge is the inability to pool T cells from multiple donors due to mutual recognition as foreign cells. In this invention Stanford researchers have developed technology to be able to successfully pool and simultaneously test T cells from multiple human donors without adverse reactions between the T cells from different donors.
Stage of Development
In vitro
Applications
- Cell therapy development
- Cell therapy diagnostic
Advantages
- Scaleable
- Significantly cheaper and less resource intensive
Patent Status
Provisional patent application filed
Related Links
Similar Technologies
-
Oxidative Stress is Characteristic of ME-CFS, Long COVID, and Some Autoimmunity Patients S23-075Oxidative Stress is Characteristic of ME-CFS, Long COVID, and Some Autoimmunity Patients
-
Precision Immunotherapy: AI-Powered Biomarkers for Predicting Outcomes in Advanced Esophagogastric Cancer S24-099Precision Immunotherapy: AI-Powered Biomarkers for Predicting Outcomes in Advanced Esophagogastric Cancer
-
CytoTrace2: Methods and Systems for Determining Phenotypic States from Genomic Data with Interpretable AI S24-057CytoTrace2: Methods and Systems for Determining Phenotypic States from Genomic Data with Interpretable AI